Compare DexCom, Inc. (DXCM) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Lululemon Athletica Inc — how do they compare? DexCom, Inc. trades at $77.55 (market cap $28.06B), while Lululemon Athletica Inc trades at $118.62 (market cap $13.33B). The key difference: DexCom, Inc. is far larger — about 2.1× Lululemon Athletica Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | LULU | |
|---|---|---|
Market Cap | $28.06B | $13.33B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $233.31 |
52-Week Low | $54.84 | $105.43 |
Enterprise Value | $27.03B | $13.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Lululemon trades at $119.05, up 1.47% with neutral technical indicators and mixed sentiment. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.69 beating expectations of $1.67. Revenue grew to $10.59B in 2025 with robust profitability metrics including 55.7% gross margin and 32.03% ROE. Recent developments include a $30M investment in nylon recycling startup Syntetica and resolution of board disputes with founder Chip Wilson.
The outlook remains cautiously optimistic with a consensus price target of $129.29 offering 8.6% upside potential. Key opportunities include strong brand positioning and consistent execution, while risks involve competitive pressures and recent controversies affecting consumer trust. Analyst consensus leans neutral with 40.85% buy ratings versus 53.52% hold recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
